Evotec (NASDAQ:EVO) Shares Down 4.4%

Evotec SE (NASDAQ:EVO)’s stock price fell 4.4% on Thursday . The stock traded as low as $4.88 and last traded at $4.98. 19,572 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 111,222 shares. The stock had previously closed at $5.21.

Analyst Upgrades and Downgrades

Several research firms have weighed in on EVO. Deutsche Bank Aktiengesellschaft lowered Evotec from a “buy” rating to a “hold” rating in a research note on Thursday. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Evotec in a research note on Thursday, May 23rd.

Evotec Trading Down 2.3 %

The company has a current ratio of 1.86, a quick ratio of 1.79 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average price of $4.92 and a 200 day moving average price of $6.84.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Cetera Advisors LLC bought a new position in shares of Evotec during the first quarter worth about $188,000. Mubadala Investment Co PJSC bought a new position in Evotec in the fourth quarter valued at approximately $53,931,000. Optiver Holding B.V. grew its stake in Evotec by 643.1% in the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after purchasing an additional 69,936 shares in the last quarter. Finally, Quadrant Capital Group LLC bought a new position in Evotec in the fourth quarter valued at approximately $25,000. 5.81% of the stock is currently owned by institutional investors.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.